Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-551-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$99.24 million
Profitability
Miscellaneous
Employees398
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Radius Health (NASDAQ:RDUS) Frequently Asked Questions
What is Radius Health's stock symbol?
Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
How were Radius Health's earnings last quarter?
Radius Health Inc (NASDAQ:RDUS) announced its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.86) by $0.09. The biopharmaceutical company earned $41.04 million during the quarter, compared to the consensus estimate of $40.60 million. Radius Health had a negative net margin of 127.22% and a negative return on equity of 368.58%. Radius Health's revenue was up 81.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.99) earnings per share. View Radius Health's Earnings History.
When is Radius Health's next earnings date?
What guidance has Radius Health issued on next quarter's earnings?
Radius Health issued an update on its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $165-170 million, compared to the consensus revenue estimate of $171.6 million.
What price target have analysts set for RDUS?
6 equities research analysts have issued 1 year price targets for Radius Health's stock. Their predictions range from $22.00 to $52.00. On average, they anticipate Radius Health's share price to reach $39.00 in the next year. This suggests a possible upside of 40.7% from the stock's current price. View Analyst Price Targets for Radius Health.
What is the consensus analysts' recommendation for Radius Health?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Radius Health.
What are Wall Street analysts saying about Radius Health stock?
Here are some recent quotes from research analysts about Radius Health stock:
- 1. HC Wainwright analysts commented, "Our $26 price target is based on an 80% probability of success adjusted-DCF analysis including just Korsuva U.S. sales in CKD-aP, comprising peak IV Korsuva annual sales over $500M in the hemodialysis population, and $300M peak oral Korsuva sales in Stage 3-5 CKD (the latter even further risk-adjusted to <$100M in our model at 30% probability of success pre-Phase 2). Our DCF reflects a 10% WACC discount and 0% terminal growth beyond 2028. If our DCF valuation with IV Korsuva entirely de-risked (and oral still at 30%), all else equal, would yield a CKD-aP driven valuation of $35/share. That does not yet include any explicit value for Korsuva ex-U.S."" (5/9/2019)
- 2. According to Zacks Investment Research, "Radius’ lead drug, Tymlos, continues to gain traction. In the first six weeks of 2019, the drug captured a 29% share of the U.S. anabolic osteoporosis market and more than 40% of new anabolic patient starts. Tymlos captured, on average, 20% of the U.S. anabolic osteoporosis market in 2018. In the fourth quarter, the drug’s average U.S. anabolic market share grew to 26% and achieved a 39% share of new anabolic patient starts. However, Radius suffered a setback when the European Commission refused to approve the drug. While the market for postmenopausal osteoporosis provides significant commercial potential, it is pretty crowded with the presence of drugs like Amgen’s Prolia and Lilly’s Forteo. Shares have underperformed the industry in the past twelve months." (5/6/2019)
Has Radius Health been receiving favorable news coverage?
News coverage about RDUS stock has been trending neutral on Friday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Radius Health earned a news impact score of 0.2 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Radius Health.
Who are some of Radius Health's key competitors?
Some companies that are related to Radius Health include Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), The Medicines (MDCO), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), United Therapeutics (UTHR), FibroGen (FGEN), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), Allakos (ALLK), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS) and Global Blood Therapeutics (GBT).
What other stocks do shareholders of Radius Health own?
Who are Radius Health's key executives?
Radius Health's management team includes the folowing people:
- Mr. Jesper Høiland, Pres, CEO & Director (Age 59)
- Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 47)
- Mr. Brent Hatzis-Schoch Esq., J.D., Sr. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Brian Nicholas Harvey, Advisor (Age 58)
- Dr. Stavros C. Manolagas, Co-Founder & Member of the Scientific Advisory Board
Who are Radius Health's major shareholders?
Radius Health's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.33%). Company insiders that own Radius Health stock include Anthony Rosenberg, Brent Hatzis-Schoch, Debasish Roychowdhury, Growth N V Biotech, Jesper Hoiland, Jessica Hopfield, Joseph Francis Kelly and Willard H Dere. View Institutional Ownership Trends for Radius Health.
Which institutional investors are buying Radius Health stock?
RDUS stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have bought Radius Health stock in the last two years include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland, Jessica Hopfield and Joseph Francis Kelly. View Insider Buying and Selling for Radius Health.
How do I buy shares of Radius Health?
Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Radius Health's stock price today?
One share of RDUS stock can currently be purchased for approximately $27.72.
How big of a company is Radius Health?
Radius Health has a market capitalization of $1.28 billion and generates $99.24 million in revenue each year. The biopharmaceutical company earns $-221,340,000.00 in net income (profit) each year or ($4.88) on an earnings per share basis. Radius Health employs 398 workers across the globe.View Additional Information About Radius Health.
What is Radius Health's official website?
How can I contact Radius Health?
Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]
MarketBeat Community Rating for Radius Health (NASDAQ RDUS)
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
